IL2 and colorectal carcinoma: In two randomized studies of patients undergoing resection of colorectal cancer (CRC) primary tumors (58) and hepatic metastases (57), preoperative low-dose subcutaneous (s.c.)IL-2 was associated with an improved prognosis.